A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
3 other identifiers
interventional
426
14 countries
145
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 2025
Typical duration for phase_3
145 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2025
CompletedFirst Posted
Study publicly available on registry
June 10, 2025
CompletedStudy Start
First participant enrolled
July 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 3, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 13, 2028
July 29, 2026
July 1, 2026
3.3 years
June 2, 2025
July 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14
At Week 14
Secondary Outcomes (20)
Change from baseline on the Clinical Global Impressions-Severity (CGI-S) at Week 14
At Week 14
Change from baseline on CMAI-IPA Domains at Week 14
At Week 14
Change from baseline on CMAI Total Score at Week 14
At Week 14
Number of participants with Occurrence of Response at Week 14
At Week 14
Change from baseline on the Neuropsychiatric Inventory/Neuropsychiatric Inventory -Nursing Home (NPI/NPI-NH) Total Score at Week 14
At Week 14
- +15 more secondary outcomes
Study Arms (2)
KarXT + KarX-EC
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Specified dose on specified days
Specified dose on specified days
Eligibility Criteria
You may qualify if:
- \- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:
- i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.
- ii) If no historical evidence available:
- A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.
- B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:
- Amyloid PET.
- Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.
- Mini-Mental State Examination (MMSE) score of ≤ 24 at Screening (Visit 1).
- Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:
- i) Attend all visits and report on participant's status.
- ii) Oversee participant compliance with medication and study procedures.
- iii) Participate in the study assessments and provide informed consent to participate in the study.
- History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).
- AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).
- Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score ≥ 30 at Screening (Visit 1) and Visit 2.
You may not qualify if:
- \- Medical Conditions.
- i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.
- ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder.
- iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
- iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.
- \- Prior/Concomitant Therapy.
- i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).
- A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.
- B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).
- Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (145)
Chandler Clinical Trials, LLC
Chandler, Arizona, 85224, United States
Local Institution - 2631
Chandler, Arizona, 85226-3732, United States
Local Institution - 2646
Chandler, Arizona, 85286, United States
National Institute of Clinical Research
Garden Grove, California, 92844, United States
Local Institution - 2607
Long Beach, California, 90805, United States
Accellacare
Long Beach, California, 90807, United States
Local Institution - 2627
Napa, California, 94558, United States
Local Institution - 2649
Orange, California, 92866, United States
Local Institution - 2613
Pasadena, California, 91105, United States
Local Institution - 2614
San Diego, California, 92108, United States
Local Institution - 2620
West Hills, California, 91307, United States
Local Institution - 2601
Basalt, Colorado, 81621, United States
Local Institution - 2635
Colorado Springs, Colorado, 80907, United States
Local Institution - 2632
Norwalk, Connecticut, 06851, United States
Local Institution - 2648
Aventura, Florida, 33180, United States
Envision Trials LLC
Bonita Springs, Florida, 34134-4154, United States
Key Clinical Research
Bradenton, Florida, 34207, United States
Local Institution - 2636
Doral, Florida, 33122, United States
Local Institution - 2606
Homestead, Florida, 33032, United States
Local Institution - 2633
Miami, Florida, 33137, United States
Local Institution - 2637
Miami, Florida, 33165, United States
Local Institution - 2634
Orlando, Florida, 32806, United States
IPTB Clinical Research
Tampa, Florida, 33629, United States
Agile Clinical Research Trials, LLC
Atlanta, Georgia, 30328, United States
Vitalix Clinical
Worcester, Massachusetts, 01608, United States
Local Institution - 2618
Ann Arbor, Michigan, 48105, United States
Local Institution - 2630
Saint Paul, Minnesota, 55130, United States
Hattiesburg Clinic
Hattiesburg, Mississippi, 39402, United States
Local Institution - 2603
Ozark, Missouri, 65721, United States
Las Vegas Clinical Trials
Las Vegas, Nevada, 89030, United States
Local Institution - 2650
Toms River, New Jersey, 08755, United States
Local Institution - 2647
Brooklyn, New York, 11229, United States
Richmond Behavioral Associates
Staten Island, New York, 10312, United States
Walnut Clinical Research
Valley Stream, New York, 11580, United States
West Clinical Research
Morehead City, North Carolina, 28557, United States
Velocity Clinical Research - Blue Ash
Blue Ash, Ohio, 45242, United States
Epic Medical Research, LLC - Carrolton
Carrollton, Texas, 75006, United States
Horizon Clinical Research Center - Houston
Cypress, Texas, 77429, United States
Epic Medical Research, LLC - Mesquite
Mesquite, Texas, 75150, United States
UT Health - San Antonio
San Antonio, Texas, 78229, United States
Local Institution - 2612
Bountiful, Utah, 84010, United States
EvergreenHealth Medical Center
Kirkland, Washington, 98034, United States
Local Institution - 2610
Milwaukee, Wisconsin, 53226, United States
Centro Neurobiológico y de Estrés Traumático - CENydET S.R.L.
Ciudad Autonoma de Buenos Aires, Buenos Aires, 1058, Argentina
Fundacion para el Estudio y Tratamiento de Enfermedades mentales- FETEM
Buenos Aires, 1133, Argentina
Local Institution - 2004
Buenos Aires, 1199, Argentina
Instituto Modelo de Neurología, Fundación Lennox
Córdoba, 5000, Argentina
Local Institution - 2002
Córdoba, 5000, Argentina
Instituto Médico DAMIC
Córdoba, X5003DCE, Argentina
Resolution Psychopharmacology Research Institute
Mendoza, 5502, Argentina
Biomedica Research Group
Santiago, Santiago Metropolitan, 7500710, Chile
Local Institution - 2050
Santiago, Santiago Metropolitan, 7560356, Chile
Pontificia Universidad Catolica de Chile
Santiago, Santiago Metropolitan, 8330024, Chile
Clinica Alemana
Vitacura, Santiago Metropolitan, 2511433, Chile
Local Institution - 2055
Viña del Mar, Valparaiso, 2511433, Chile
Psicomed Estudios Médicos Cía Ltda
Antofagasta, 1270244, Chile
AGE Centrum
Olomouc, Olomouc Region, 779 00, Czechia
Neuropsychiatrie
Prague, Praha 6, 160 00, Czechia
Institut neuropsychiatricke pece (INEP), Praha
Prague, Praha 8, 18600, Czechia
Neuro Health Centrum s.r.o.
Brno, South Moravian, 628 00, Czechia
NEUROHK
Choceň, 565 01, Czechia
A-SHINE s.r.o.
Pilsen, 301 00, Czechia
Local Institution - 2102
Prague, 100 000, Czechia
Local Institution - 2105
Prague, 100 00, Czechia
Vestra Clinics s.r.o.
Rychnov nad Kněžnou, 516 01, Czechia
Centre Hospitalier Universitaire Toulouse - Cité de la Santé
Toulouse, Haute-Garonne, 31000, France
Hôpital des Charpennes - Hospices Civils de Lyon (HCL)
Villeurbanne, Rhône, 69100, France
Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro
Lille, 59037, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
Limoges, 87042, France
Hopital Gui Chauliac - Chu Montpellier
Montpellier, 34295, France
Centres Memoire de Ressources et de Recherche (CMRR) - Hopital Lariboisiere-Fernand-Widal Location
Paris, 75010, France
Les Hôpitaux Universitaires de Strasbourg - Hôpital de la Robertsau
Strasbourg, 67091, France
Local Institution - 2201
Düsseldorf, 40221, Germany
Local Institution - 2205
Halle, 06120, Germany
Local Institution - 2206
Westerstede, 26655, Germany
Local Institution - 2257
Kalocsa, Bács-Kiskun county, 6300, Hungary
Local Institution - 2250
Győr, Győr-Moson-Sopron, 0, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hajdú-Bihar, 4031, Hungary
Local Institution - 2254
Gyöngyös, Heves County, 3200, Hungary
Local Institution - 2256
Budapest, 1033, Hungary
Local Institution - 2255
Budapest, 1036, Hungary
Local Institution - 2251
Budapest, 1083, Hungary
Semmelweis Egyetem
Budapest, 1083, Hungary
The Chaim Sheba Medical Center
Ramat Gan, Central District, 5262000, Israel
Local Institution - 2302
Petch Tikva, IL, 49100, Israel
Sanz MC, Laniado Hospital
Netanya, 4244916, Israel
The Israeli Alzheimer Medical Center
Ramat Gan, 5265601, Israel
Bayit Balev Ltd.
Rishon Le'Tzion, 7590653, Israel
University of Naples Federico II
Naples, Campania, 80131, Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I - Viale del Policlinico 155
Rome, Lazio, 00185, Italy
Azienda Ospedaliero-Universitaria Sant'Andrea
Rome, Lazio, 00189, Italy
Auxologico IRCCS - Auxologico San Luca
Milan, Lombardy, 20149, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, PI, 56126, Italy
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, 25123, Italy
Local Institution - 2355
Isernia, 86077, Italy
Fondazione Policlinico Gemelli IRCCS
Roma, 00168, Italy
Centrum Medyczne HCP Szpital im. Jana Pawla II
Poznan, Greater Poland Voivodeship, 61-485, Poland
Centrum Medyczne NEUROMED
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-163, Poland
M2M Med
Chorzów, 41-500, Poland
Centrum In Psyche Spersonalizowanej Psychiatrii I Terapii
Katowice, 40-146, Poland
Local Institution - 2458
Krakow, 31-505, Poland
Local Institution - 2451
Lublin, 20-064, Poland
Local Institution - 2452
Lublin, 20-064, Poland
RCMed Oddzial Sochaczew
Sochaczew, 96-500, Poland
Local Institution - 2457
Wroclaw, 53-659, Poland
Local Institution - 2641
San Juan, 00917, Puerto Rico
CMRC Headlands
San Juan, 00918, Puerto Rico
Instituto De Neurologia Dra. Ivonne Fraga
San Juan, 00918, Puerto Rico
Local Institution - 2639
San Juan, 00918, Puerto Rico
Inha University Hospital
Incheon, Incheon Gwang'yeogsi, 22332, South Korea
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea
Konkuk University Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], 05030, South Korea
Local Institution - 2406
Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea
Kyungpook National University Chilgok Hospital
Deagu, Taegu-Kwangyǒkshi, 41404, South Korea
Gachon University Gil Medical Center
Incheon, 405-760, South Korea
Asan Medical Center
Seoul, 05505, South Korea
Gangnam Severance Hospital, Yonsei University Health System
Seoul, 06273, South Korea
SMG-SNU Borame Medical Center
Seoul, 07061, South Korea
The Catholic University of Korea, Yeouido St.Mary's Hospital
Seoul, 07345, South Korea
Communal non-commercial enterprise "Cherkasy regional psychiatric hospital of Cherkasy regional council"
Smila, Cherkasy Oblast, 20708, Ukraine
MUNICIPAL NON-COMMERCIAL COMPANY Dnipropetrovsk Multiprofile Clinical Hospital for Provision of Psychiatric Care DRC
Dnipro, Dnipropetrovsk Oblast, 49115, Ukraine
Municipal Non-Commercial Enterprise "Khmelnytskyi Regional Psychiatric Care Facility" of the Khmelnytskyi Regional Council
Skarzhyntsi, Khmelnytskyi Oblast, 32120, Ukraine
Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association"
Hlevakha, Kyiv Oblast, 08631, Ukraine
COMMUNAL NONCOMMERCIAL ENTERPRISE of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital"
Lviv, Lviv Oblast, 79021, Ukraine
Municipal Non-Commercial Enterprise "Odesa Regional Medical Centre of Mental Health" of Odesa Regional Council
Oleksandrivka, Odesa Oblast, 67513, Ukraine
Communal non-profit enterprise "Vinnytsia Regional Clinical Psycho-Neurological Hospital n.a. acad. O.I. Yushchenko of VRC"
Vinnytsia, Vinnytsia Oblast, 21037, Ukraine
Local Institution - 2560
Lutsk, Volyn Oblast, 43005, Ukraine
CNCE "Clinical Facility for Mental Health Care "PSYCHIATRY" of executive body of Kyiv City Council (KCSA)"
Hlevakha, 08631, Ukraine
Communal Non-Commercial Enterprise "Regional Clinical Psychiatric Hospital of the Kirovohrad Regional Council
Kropyvnytskyi, 25491, Ukraine
Local Institution - 2565
Kyiv, 01030, Ukraine
CNCE "Clinical Facility for Mental Health Care "PSYCHIATRY" of executive body of Kyiv City Council (KCSA)
Kyiv, 04080, Ukraine
"Medical Centre "Neuroclinic" LLC
Lviv, 79035, Ukraine
Limited Liability Company "Iqmed"
Lviv, 79035, Ukraine
Communal Enterprise "Regional Institution of Mental Psychiatric Care of the Poltava Regional Council"
Poltava, 36013, Ukraine
Local Institution - 2562
Ternopil, 46027, Ukraine
Lancashire & South Cumbria NHS Foundation Trust
Preston, Lancashire, PR2 9HT, United Kingdom
Surrey and Borders Partnership NHS Foundation Trust
Chertsey, Surrey, KT16 9AU, United Kingdom
Local Institution - 2502
Cambridge, CB21 5EF, United Kingdom
South London and Maudsley NHS Foundation Trust
London, SE5 8AZ, United Kingdom
Local Institution - 2500
London, W12 0NN, United Kingdom
NeuroClin Glasgow
Motherwell, ML1 4UF, United Kingdom
Cornwall Partnership NHS Foundation Trust
Redruth, TR15 3QE, United Kingdom
Sheffield Health and Social care NHS Foundation Trust
Sheffield, S5 7JT, United Kingdom
Local Institution - 2509
Stafford, ST16 3SR, United Kingdom
Black Country Healthcare NHS Foundation Trust
Wolverhampton, WV4 5HN, United Kingdom
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 2, 2025
First Posted
June 10, 2025
Study Start
July 16, 2025
Primary Completion (Estimated)
November 3, 2028
Study Completion (Estimated)
November 13, 2028
Last Updated
July 29, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html